Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TCM's Output To Hit RMB 400 Billion Over Next Decade

This article was originally published in PharmAsia News

Executive Summary

At the recent 2009 International Conference for Bioeconomy, the Ministry of Science and Technology's China National Center for Biotechnology Development disclosed that the country will further push for TCM modernization and establish a healthcare system of integrating Western and Chinese medicine. TCM industry value is expected to hit RMB 400 billion ($58.5 billion) over the next 10 years. In addition, China will make TCM healthcare a key pillar for the population, such that 85 percent of rural residents can access such medical services. TCM industry value has been increasing at an average annual rate of 20 percent in recent years to reach almost a hundred billion renminbi, higher than the pharmaceutical industry's average. (Click here for more - Chinese Language)

You may also be interested in...



Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

UsernamePublicRestriction

Register

SC072387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel